Advanced Viral Research Corp. to Initiate Phase II Trial in Cancer Patients

YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB:ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today plans to initiate a Phase II clinical trial to evaluate the effectiveness of its compound AVR118 in the treatment of cachexia-related symptoms in cancer patients. The trial will be run at the McGill University Health Centre (MUHC) in Montreal, Quebec. MUHC is one of the most comprehensive academic health centers in North America, representing five teaching hospitals affiliated with the Faculty of Medicine of McGill University.

Back to news